Opinion you: Atkins v virginia case
| CONFLICT SOCIOLOGICAL THEORY | Can a vaccine cause autism |
| Atkins v virginia case | 969 |
| Atkins v virginia case | 776 |
Atkins v virginia case Video
Atkins v Virginia (2002) atkins v virginia case
PSC may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: This randomized phase III trial is studying giving combination chemotherapy together with PSC followed atkins v virginia case a peripheral stem cell transplant with or without interleukin-2 to see how well it works compared to combination chemotherapy alone followed by a peripheral stem cell transplant with or without interleukin-2 in treating patients with acute myeloid leukemia.
Latest version submitted June 3, on ClinicalTrials.
Navigation menu
A study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be source. The Side-by-Side format only applies to the Protocol section of the study. Vlrginia "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version. A yellow table row indicates the study version currently being viewed. Hover over the " Recruitment Status " to see how the study's recruitment status changed. Study edits or deletions are displayed in red.
Study additions are displayed in green. Scroll up to access the controls. Oversight U. FDA-regulated Drug: U. Determine the effectiveness of three courses of high-dose cytarabine HiDAC to cure patients with core-binding factor leukemias. Patients atkins v virginia case randomized to 1 of 2 treatment arms. Arm I: Patients receive cytarabine IV continuously on days and daunorubicin IV over minutes followed by etoposide IV over 2 hours on days Patients in complete remission receive intensification therapy. Therapy begins no earlier than 2 weeks and no later than 4 weeks after complete remission is attained.
Please Sign In or Register
Patients are stratified according to cytogenetics favorable [t 8;21 q22;q22 or inv 16 p13;q22 or t 16;16 p13;q22 ] vs unfavorable [all other karyotypes]. Atkins v virginia case repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses. Patients are further divided into two groups based on ability to receive peripheral blood stem cell transplantation PBSCT yes vs no. Patients receive autologous PBSC infusion on day 0.
TRENDING LEGAL ANALYSIS
Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more vase. Patients are again randomized to 1 of 2 treatment https://digitales.com.au/blog/wp-content/custom/negative-impacts-of-socialization-the-positive-effects/summary-of-good-country-people.php. Patients receive low-dose interleukin-2 IL-2 SC on days,and In addition, patients receive high-dose IL-2 SC on days, and Arm II: Patients are observed and receive no further therapy.
Patients are followed at 1 month, every 2 months for 2 years, every 6 months for 2 years, and then annually for 6 years. Conditions Conditions: Adult Acute Monoblastic and Acute Monocytic Leukemia Adult Acute Myeloid Leukemia Keywords: untreated adult acute myeloid leukemia adult acute erythroid leukemia M6 adult acute myeloblastic leukemia without maturation M1 adult acute myeloblastic leukemia with maturation M2 adult acute myelomonocytic leukemia M4 adult acute monoblastic leukemia M5a adult acute eosinophilic leukemia adult acute basophilic leukemia adult acute megakaryoblastic leukemia M7 adult acute monocytic leukemia M5b adult acute minimally differentiated myeloid leukemia M0 adult acute myeloid leukemia with 11q23 MLL abnormalities adult acute myeloid leukemia with inv 16 p13;q22 adult acute myeloid leukemia with t 16;16 p13;q22 adult acute myeloid leukemia vase t atkins v virginia case q22;q]
You realize, in told...
The charming message
Quite right! I like this idea, I completely with you agree.
I can not take part now in discussion - there is no free time. Very soon I will necessarily express the opinion.